Purpose: Fibrosis accounts for approximately 50% of histological findings at post-chemotherapy retroperitoneal lymph node dissection, and is associated with reported relapse rates of 10% to 15%. We characterized patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection and identified predictors of adverse outcomes in this group. Materials and Methods: We reviewed the medical records of men who underwent post-chemotherapy retroperitoneal lymph node dissection between 1989 and 2013 with histological findings of necrosis/fibrosis. With few exceptions post-chemotherapy retroperitoneal lymph node dissection after 1999 was performed with a bilateral template. Clinical, pathological and treatment related data were reported. Cox regression models were built to identify predictors of disease recurrence. Results: The study cohort included 598 men with a median age of 32 years (IQR 25e38). Most cases (397 of 547, 73%) were classified as IGCCCG good risk, with no significant differences in risk classification before and after 1999 (p¼0.55). Median followup was 7.3 years (IQR 3.2e12.3). The 5-year recurrence-free and overall survival rates were 94% and 96%, respectively. Overall 36 patients had disease recurrence, most of which was distant or outside the retroperitoneal lymph node dissection template. Procedures performed after 1999 and the presence of embryonal cell carcinoma on primary histology were associated with improved recurrence-free survival on multivariate analysis (p <0.01). Conclusions: Disease recurrence in patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection is an uncommon yet significant event, which is less likely to occur in patients treated after 1999 and in those with embryonal carcinoma on primary histology.
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* Equal study contribution. 3e7 According to an initial report each of these histologies appeared in approximately a third of the cases. 3 However, in recent studies necrosis/fibrosis comprised 41% to 49% of histological findings, teratomas 40% to 42% and viable GCTs apparent in only 11% to 17% of lesions. 4e6 These rates are markedly different after second line chemotherapy, with viable GCTs noted in 50% of the lesions, teratomas in 40% and necrosis/fibrosis in 10%. 7 Despite the presence of a presumably negative pathology, patients with necrosis/fibrosis undergoing PC-RPLND have relapse rates of 10% to 15%. 2 Furthermore, the outcome of patients with fibrosis improved when operated on in recent rather than early years, consistent with the improvement in surgical technique. 6 In addition, patients with elevated serum tumor markers who underwent PC-RPLND with evidence of fibrosis had normalization of serum markers after surgery. 8 Finally, genetic analysis of stromal cells from fibrotic lesions after PC-RPLND revealed allelic loss in 85% of specimens, including loss of chromosome arm 12p, a hallmark finding in germ cell neoplasia, in 33% of cases. These genetic alterations suggest that fibrotic lesions contain cells that are derived from tumor progenitor cells, challenging the concept that these cells are benign. 9 Taken together, these findings suggest that a subset of patients may derive benefit from RPLND even in the presence of a seemingly negative pathology.
While previous studies have reported on the clinicopathological characteristics of patients with viable GCT and teratoma at post-chemotherapy RPLND, 10e12 less is known regarding patients with findings of fibrosis. In the current study we characterized patients with necrosis/fibrosis at PC-RPLND and identified predictors of adverse outcomes in this group.
MATERIALS AND METHODS
After obtaining institutional review board approval we queried our prospectively maintained surgical database and identified 598 patients who underwent PC-RPLND after first or second line chemotherapy for seminoma and NSGCT between 1989 and 2013 with histological findings of necrosis/fibrosis.
Pretreatment clinical and pathological information collected included patient age, histological subtype of the primary tumor (seminoma, embryonal carcinoma, yolk sac tumor, teratoma, choriocarcinoma and other), IGCCCG risk category (good, intermediate, poor) and pre-chemotherapy node size as determined by the transverse diameter of the largest mass on axial imaging. 13 All primary tumor specimens were reviewed by genitourinary pathologists at our institution to verify tumor histology. All patients underwent induction chemotherapy. The use of second line chemotherapy, post-chemotherapy node size and the presence of elevated serum tumor markers after the completion of chemotherapy were noted. Information regarding surgical treatment included the year in which RPLND was performed and the template used for the resection (bilateral, unilateral or mass resection). PC-RPLND after 1999 was performed with a bilateral template. After the operation the patients were followed with serum tumor markers and periodical axial imaging. Disease recurrence was defined as the presence of imaging findings suggestive of recurrence with or without elevated serum tumor markers, or elevated markers in the absence of a mass on followup imaging. Recurrence location was noted and categorized as locoregional or distant. Locoregional recurrences were further categorized as intra-template, within the boundaries of a standard bilateral template, and extra-template.
The primary study end point was disease recurrence. The probability of RFS was analyzed using the Kaplan-Meier method. Univariate Cox proportional hazards models were used to examine the association among primary histological subtype, IGCCCG risk category, the use of second line chemotherapy, post-chemotherapy node size, the year and template of RPLND and disease recurrence. A backward stepwise elimination process was used to select variables for the multivariate analysis. Multivariate Cox regression models were built to identify independent predictors of disease recurrence. All statistical analyses were 2-sided with p <0.05 considered statistically significant. SPSSÒ Statistics for Windows version 23.0 was used for all data analyses.
RESULTS
The study cohort included 598 men with a median age of 32 years (IQR 25e38). Clinical characteristics of the study cohort are reported in table 1. The primary tumor site was the testis in 569 patients (95%) and retroperitoneum in 29 (5%). Tumor histology was available for 574 patients, including 42 (7%) with pure seminoma, 462 (80%) with NSGCT and 70 (12%) with prior diagnosis of a germ cell tumor, who did not have histological evidence of a viable germ cell tumor at orchiectomy, most of whom had fibrosis or a burnt-out scar. The most common histological subtype was embryonal carcinoma, apparent in 404 patients (70%). Most cases (397 of 547, 73%) were classified as good risk according to the IGCCCG risk classification. No significant differences in IGCCCG risk classification were observed before and after 1999 (p¼0.55). A minority of patients received second line chemotherapy (46, 8%) and most had normal serum tumor markers before RPLND (564, 94%). Bilateral RPLND was performed in 419 patients (70%). After 1999, 371 of 382 patients (97%) underwent bilateral template RPLND while 11 of 382 (3%) underwent mass resection alone. Of these 11 all except 1 had prior RPLND and were redo resections performed after receiving chemotherapy. One patient had seminoma with a severe desmoplastic reaction and underwent resection of mass. Data regarding serum tumor marker status after surgery were available for 30 of 34 patients with elevated tumor markers before PC-RPLND, all of whom had normalization of markers after surgery. Two patients with elevated serum tumor markers before PC-RPLND had disease recurrence during followup.
Median followup for patients without disease recurrence was 7.3 years (IQR 3.2e12.3). Median time to disease recurrence was 5.5 months (IQR 2e13.5). A total of 36 patients had disease recurrence at 1 or more sites, with 27 (75%) distant recurrence and 14 (39%) locoregional recurrence. Six patients with a locoregional recurrence had a concurrent distant recurrence and, therefore, only 8 (1.3% of the entire cohort) had a locoregional recurrence alone. Among the 14 locoregional recurrences intra-template recurrences were observed in 2 of 3 patients who underwent mass resection, 6 of 7 who underwent unilateral template RPLND and 1 of 4 who underwent bilateral template RPLND (p¼0.129). Elevated serum tumor markers were measured at recurrence in 22 of 36 patients (61%). One patient had a serum tumor marker elevation without evidence of recurrent disease on axial imaging. Recurrence histology was available for 21 patients, including 9 (43%) with viable GCT, 8 (38%) with fibrosis, 3 (14%) with teratoma, and 1 (5%) with viable GCT and teratoma.
The 5-year recurrence-free and overall survival rates for the entire cohort were 94% and 96%, respectively. On univariate analysis intermediate or poor IGCCCG risk category, the use of second line chemotherapy and post-chemotherapy node size greater than 1 cm were significantly associated with disease recurrence after PC-RPLND. The presence of embryonal carcinoma in the primary tumor, RPLND performed after 1999 and the use of a bilateral template were significantly associated with a lower rate of disease recurrence. The presence of a teratomatous element on primary histology was not significantly associated with disease recurrence (table 2). The 5-year RFS rate was 97% for patients with embryonal carcinoma in the initial tumor compared to 87% for those without. In addition, 5-year RFS was 96%, 90% and 89% for patients who underwent bilateral RPLND, unilateral RPLND and mass resection, respectively (see figure) . The estimated 5-year RFS was 97.8% for patients with nodes 1 cm or smaller compared to 92.3% for those with nodes larger than 1 cm (p¼0.015). Embryonal carcinoma histology and year of RPLND remained significant predictors of outcome when included in a multivariate Cox regression model (table 2) . In a similar multivariate analysis performed on the subgroup of patients who received induction chemotherapy only (552), the presence of embryonal carcinoma (HR 0.34, 95% CI 0.16e0.72, p¼0.005) and surgery performed in 
DISCUSSION
In the current study we evaluated 598 patients who underwent PC-RPLND with a histological finding of fibrosis. Most patients had a good IGCCCG risk category (73%) and did not require second line chemotherapy (92%) before surgery. The overall 5-year RFS rate was 94%. The presence of embryonal carcinoma in the primary histology was significantly associated with a better outcome on multivariate analysis (p <0.001). Similarly, patients treated after 1999 had a better outcome (p¼0.002), which may be related to the widespread use of a bilateral surgical template, among other causes, during these years. Fibrosis/necrosis is found in 40% to 50% of residual masses in patients with advanced germ cell tumors treated with PC-RPLND.
14 Several authors consider fibrosis/necrosis a benign finding that may not require extensive surgery. Therefore, efforts were made to establish prognostic models capable of predicting the presence of fibrosis/necrosis on PC-RPLND. 15, 16 However, since these models have a false-positive rate of approximately 20% with regard to the correct detection of fibrosis and necrosis, they may be unsuitable for routine clinical use. 17 Furthermore, several studies have suggested the nature of fibrosis may not be benign. Cheng et al performed genetic analyses on the dissection specimens of 27 patients who were found to have fibrosis or necrosis at PC-RPLND. 9 Stromal cells in 88% of these specimens displayed allelic loss at multiple DNA loci and/or chromosome arm 12p abnormalities, suggesting these cells are of neoplastic origin and may be the source of secondary sarcomas. In addition, normalization of serum tumor markers in patients undergoing PC-RPLND with a histological finding of fibrosis/ necrosis suggests that surgery may be beneficial in this setting. 8 Thus, PC-RPLND at a high volume center remains necessary for histological diagnosis, staging and treatment of residual masses after platinum based chemotherapy regardless of the final pathology. 18 Patients with viable tumor at post-chemotherapy RPLND are at increased risk for disease progression, with an estimated 5-year RFS rate of 50%. An intermediate or poor IGCCCG risk classification was associated with decreased RFS in these patients. 10 The 5-year RFS of patients with residual teratoma at PC-RPLND was 81% to 83%. Significant predictors of an adverse outcome included residual mass size, IGCCCG risk classification, elevated post-chemotherapy alpha fetoprotein levels and mediastinal involvement at presentation. 11, 12 In the current study the 5-year RFS for patients with fibrosis at PC-RPLND was 94%, which was substantially higher than that of viable GCT and teratoma. The presence of embryonal carcinoma histology and RPLND performed in recent years were associated with improvement in RFS.
Previous studies have supported the use of unilateral modified templates in well selected patients for whom the location of the retroperitoneal mass corresponded with the primary landing zone of the tumor bearing testicle and the residual mass diameter measured 5 cm or less. 19, 20 In these studies recurrence rates were low, with only 1 reported recurrence within the boundaries of the surgical template. 19, 20 In the Kaplan-Meier curves of RFS after surgery stratified by presence of embryonal carcinoma on initial histology (A) and PC-RPLND templates (B).
current study "pure" locoregional recurrences were uncommon, observed in 1.3% of the entire cohort at a median followup of 12 months (IQR 5e19.25). However, among 14 patients with locoregional recurrences, intra-template recurrences were found in 6 of 7 who underwent unilateral template RPLND, 2 of 3 who underwent mass resection and 1 of 4 treated with a full bilateral template. While differences in inclusion criteria may explain the relatively higher intra-template recurrence rates in patients undergoing unilateral resection, if supported by studies with larger cohorts, these findings may justify performing full bilateral RPLND in the setting of fibrosis. In a previous study at our center 15-month relapse rates were evaluated in a cohort of patients with advanced NSGCT who underwent PC-RPLND between 1989 and 2002. 6 When comparing patients treated between 1989 and 1997 and 1998 and 2002, a significant improvement in outcome was seen in the latter years. This decrease in the probability of relapse was apparent in patients with fibrosis or teratoma. However, patients with persistent viable GCT did not show improvement in RFS during the years of the study. 6 In the current study, focused on patients with fibrosis on PC-RPLND, a similar improvement in outcome was observed when comparing those who were operated on between 1989 and 1998 and 1999 to 2013, suggesting the improvement in outcome was sustained in recent years. Carver et al reported that the improvement in outcome was related in part to stage migration but was also significantly related to the use of complete RPLND (unilateral or bilateral) rather than resection of the residual mass alone. 6 Our current findings suggest that the use of bilateral template RPLND rather than unilateral template or mass resection alone may be associated with a better outcome. However, larger studies are required to support the importance of adequate surgery in this setting. These findings are consistent with the current National Comprehensive Cancer Network Ò guidelines suggesting that a full bilateral template RPLND should be performed in all cases of RPLND after chemotherapy. 18 The presence of embryonal carcinoma histology in the primary tumor was significantly associated with improved RFS on multivariate analysis in the current study. Previous studies evaluating patients with clinical stage I NSGCT showed that a high percentage of embryonal carcinoma in the primary tumor predicted the presence of occult retroperitoneal disease and a higher pathological stage. 21, 22 These seemingly inconsistent findings are likely the result of the different populations studied and the high sensitivity of embryonal carcinoma to cisplatin based chemotherapy. Multiple in vitro studies performed on embryonal carcinoma cell lines have shown that these cells are highly sensitive to DNA damaging agents, especially cisplatin. The high rate of embryonal carcinoma component in mixed germ cell tumors may explain the general high chemosensitivity and curability of these tumors in the clinical setting. 23, 24 Therefore, patients with an embryonal carcinoma component in the primary tumor may have responded better to cisplatin based chemotherapy, leading to a lower recurrence rate after PC-RPLND. Further studies are required to evaluate the reproducibility of this finding in other cohorts of patients undergoing PC-RPLND and to identify causes of this association.
The limitations of the current study include its retrospective nature and the possibility of a selection and referral bias. In addition, the study period extended over 25 years, during which time several changes in treatment policy may have occurred, influencing the current results. The relatively small number of events limited our ability to include all predictive variables in the multivariable model. Finally, as the current study is a single center study, our findings may not be generalizable to additional cohorts.
CONCLUSIONS
Disease recurrence in patients with fibrosis at PC-RPLND is an uncommon yet significant event, occurring more often in patients treated before 1999, a large percentage of whom were treated with unilateral RPLND or mass resection. The data suggest that the presence of embryonal carcinoma in the primary tumor is associated with a lower relapse rate in patients with fibrosis at PC-RPLND, possibly due to an increased sensitivity to chemotherapy. The use of a bilateral template was associated with a better outcome on univariate analysis. However, further studies are required to validate these findings when adjusting for additional factors. nonnegligible risk of recurrence among such patients, and whether it must be accounted for in terms of surveillance and counseling. Thus, the goal of current research must be specifically targeted to characterizing the molecular pathways driving such tumor biology among those bad actors in an effort to develop a more personalized approach in this patient population. 1, 2 
